Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus

Authors:

Abstract
Objective Cutaneous neonatal lupus (cNL) occurs in possibly 5%–16% of anti-Ro±anti-La antibody–exposed infants. Data suggest in utero exposure to hydroxychloroquine (HCQ) may prevent cardiac NL. The aim was to assess whether in utero exposure to HCQ decreases the risk of cNL and/or delays onset. Methods A multicentre case–control study was performed with 122 cNL cases and 434 controls born to women with a rheumatological disease who had documentation of maternal anti-Ro±anti-La antibodies at pregnancy and confirmation of medication use and the child’s outcome. A secondary analysis was performed on 262 cNL cases, irrespective of maternal diagnosis, to determine if HCQ delayed time to cNL onset. Results Twenty (16%) cNL cases were exposed to HCQ compared with 146 (34%) controls (OR 0.4 (95% CI 0.2 to 0.6); pConclusion Exposure to HCQ was associated with a reduced risk of cNL. Among cNL cases, those exposed to HCQ tend to have later onset of rash. Both findings suggest a protective effect of HCQ on cNL.
Funding Information
  • Lupus Foundation of America LFA Lifeline Program grant to JPB
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD079951-01A1 and R03 HD069986)
  • National Institute of Arthritis and Musculoskeletal and Skin Disease (5R37AR042455)

This publication has 35 references indexed in Scilit: